Patent Settlements Blocking Authorized Generics May Get Supreme Court Review
This article was originally published in The Pink Sheet Daily
Executive Summary
GlaxoSmithKline and Teva hope that lower court disagreements, if not exactly a circuit split, will be enough to get high court to revisit its Actavis decision.
You may also be interested in...
Patent Settlements: FTC Gets Teva To Eschew 'No-Authorized Generic' Deals
Global settlement resolves charges against Teva in three pending FTC antitrust suits and expands terms of 2015 consent decree.
Pay-For-Delay Deals May Be Smaller After Supreme Court Okays FTC Suits
Justices rule FTC can make its case in court that Solvay’s reverse payment settlement with Actavis and two other generic companies was anticompetitive; GPhA says opinion could decrease the number of patent challenges by generic manufacturers, but Actavis pledges to continue defending these deals.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.